The degree of respiratory depression according to the effect-site concentration in remimazolam target-controlled infusion: A randomised controlled trial
Authors' conclusion
Remimazolam infusion, like that of other benzodiazepines, led to respiratory depression, which was more prominent at higher target effect-site concentrations.
Study context
- Population
- Patients scheduled for GA, tertiary hospital, Suwon, South Korea, April–November 2022
- Participants
- 107 patients
- Comparison
- RMZ-500 vs RMZ-1000 vs RMZ-1500
- RMZ-500n = 36reference
- RMZ-1000n = 35
- RMZ-1500n = 36
- Primary endpoint
- Incidence of each respiratory support, respiratory variables and loss of consciousness
- Follow-up
- 10 min after remimazolam TCI
Methodological detailsprospective, double-blind
- Prospective
- Double-blind
Primary result
As reported in the abstract
Respiratory support
- Nearly identical frequencies between RMZ-1000 and RMZ-1500
- RMZ-1000 vs RMZ-500: P < 0.001
- RMZ-1500 vs RMZ-500: P < 0.001
Further findings
Assisted ventilation · significantly lower in RMZ-500
P < 0.001
| Outcome | RMZ-500 | RMZ-1000 | RMZ-1500 | P value |
|---|---|---|---|---|
| Loss of consciousness | 86.1% | all patients | all patients | P = 0.010 |
Tidal volume and respiratory rate vs baseline (patients with spontaneous respiration) · 5 and 10 min
- Tidal volume decreased, all groups
- 41 to 48%
- Respiratory rate increased, all groups
- 118 to 158%
- P < 0.001 vs baseline in all groups
Original publication
The degree of respiratory depression according to the effect-site concentration in remimazolam target-controlled infusion: A randomised controlled trial. Eur J Anaesthesiol. Published 29 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →